Reaxa scales up EnCat production
Successful scale-up of the production of Reaxa's lead encapsulated catalysts (EnCats), for use in pharma applications, has been achieved. Manufacture of larger batch sizes (7 to 25 kgs) has led to significantly lower costs, enabling the company to offer price reductions.
Successful scale-up of the production of Reaxa's lead encapsulated catalysts (EnCats), for use in pharma applications, has been achieved. Manufacture of larger batch sizes (7 to 25 kgs) has led to significantly lower costs, enabling the company to offer price reductions.
The catalyst technologies company has been able to lower prices after successful Pd (II) EnCat 30 and Pd(0) EnCat 30NP scale-up at UK toll manufacturers, where processes have been established at 7 - 8kg, and proven at 25kg batch sizes. Product uptake has also been a contributing factor, says the company.
In a separate development, Reaxa has established and scaled-up production of its encapsulated osmium tetroxide (Os EnCat) product at 200g and 2 kilo scale batch sizes.
"These are important milestones for Reaxa, which start to make EnCats more cost effective for r&d users," said Reaxa ceo Dr Pete Jackson.
Reaxa's catalyst and resin technologies are designed to aid the production of new drugs by simplifying processes and reducing precious metal contamination or loss in complex processes.